Shekeab Jauhari, MD joins Florida Cancer Specialists as Drug Development Leader

Sarah Cannon Research Institute at FCS is expanding access to Phase 1 clinical research at new site in Lake Mary

Fort Myers, Fla., December 3, 2019 — Florida Cancer Specialists & Research Institute (FCS) is pleased to announce the addition of Shekeab Jauhari, MD as a principal investigator on its research team. Dr. Jauhari is a medical oncologist/hematologist who will be leading Phase 1 clinical trials at the newest FCS Drug Development Unit in Lake Mary, FL, which is part of Sarah Cannon Research Institute (Sarah Cannon) and scheduled to open in early 2020. As a strategic research site for Sarah Cannon, one of the leading clinical research organizations in the world, FCS conducts clinical trials at more than 36 locations throughout the state.


Dr. Jauhari earned his medical degree from the University of Miami Miller School of Medicine. He completed his internship and residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia, PA. He went on to complete his fellowship training in hematology and oncology at Duke University in Durham, NC.   

His numerous academic honors include The ASCO® Foundation’s Conquer Cancer Young Investigator Award. During his fellowship at Duke University, he was closely involved in Phase I clinical trials and was a participant in the American Society of Hematology (ASH) Clinical Research Training Institute. He has authored many hematologic malignancy publications, which focused on the study of lymphomas and immune-based treatment approaches.

“Dr. Jauhari has extensive training in oncology research and shares our passion for expanding access to cutting-edge therapies,” said Manish R. Patel, MD, director of drug development, Sarah Cannon Research Institute at FCS. “I look forward to working with Dr. Jauhari and his team, as our early phase trial units in Sarasota and Lake Mary will work collaboratively to serve patients who vitally need advanced treatment options.”

“As a strategic research site for Sarah Cannon, more than 250 FCS patients are enrolled in over 50 Phase 1 trials each year,” said FCS Chief Executive Officer Brad Prechtl, MBA. “Dr. Jauhari’s arrival means that more patients will have access to the newest, most cutting-edge treatment therapies close to home.”

FCS President & Managing Physician Lucio N. Gordan, MD added, “Clinical trials play a critical role in improving cancer treatments. We are delighted to expand our cutting-edge research with Dr. Jauhari’s capable leadership and focus on clinical excellence.”

“Over the last two decades, Florida Cancer Specialists and Sarah Cannon have partnered to advance therapies for patients by offering clinical trials closer to where they live,” said Sarah Cannon’s President of Clinical Operations and Chief Medical Officer Howard A. “Skip” Burris, MD. “With the addition of Dr. Jauhari and our newest Lake Mary location, we are making a greater impact for patients who need novel treatment options in their communities.”

The 25,000 square-foot Drug Development Unit, Sarah Cannon Research Institute at FCS, will be a part of FCS’s newest treatment facility, which will combine medical oncology services and Phase 1 clinical trial options for cancer patients in one convenient location, 805 Currency Circle, Lake Mary, FL.  It is scheduled to open in January 2020.


About Florida Cancer Specialists & Research Institute, LLC: (
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past 4 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy.  Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

Since 2005, Florida Cancer Specialists has been a strategic research site for Sarah Cannon Research Institute, with special focus on early phase research and drug development.

About Sarah Cannon Research Institute
Focused on advancing therapies for patients, Sarah Cannon Research Institute is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. A leader in drug development, Sarah Cannon has led more than 400 first-in-human clinical trials since its inception in 1993 and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations. For more information, visit

For More Information Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
(770) 365.6168

Florida Cancer Specialists & Research Institute
Michelle Robey, Director of Marketing & Communications
(813) 767-9398